ArticleInternational journal of clinical and experimental pathology2019
Dihydrofolate reductase as a predictor for poor response to platinum-based chemotherapy in epithelial ovarian cancer.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Prognostic Significance ofBiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlatinum-based chemotherapy is the first line chemotherapy regimen for ovarian cancer patients. However, chemotherapy resistance is observed in a large proportion of patients. It is urgently needed to investigate prognostic biomarkers for chemo-sensitivity in ovarian cancer.
methodsDihydrofolate reductase (DHFR) expression was measured by immunohistochemical staining in 108 specimens, as well as DHFR mRNA variants with qRT-PCR assays. The correlation between DHFR expression and platinum-based chemotherapy response was analyzed. The prognostic significance of DHFR expression was evaluated in ovarian cancer.
resultsPositive DHFR expression was observed in 48 specimens, which was correlated to chemotherapy resistance in ovarian cancer patients. Elevated DHFR2 mRNA expression, rather than DHFR1, was observed in chemotherapy resistant tumors. Positive DHFR expression was correlated with higher histologic grade in ovarian cancer (P = 0.014). Kaplan-Meier analysis indicated that DHFR positive expression predicted poor disease-free survival (DFS) (P = 0.040), but not overall survival (OS) of ovarian cancer patients (P = 0.706). The prognostic value was further supported by TCGA data analysis. Cox regression analysis indicated that positive DHFR expression was an independent detrimental factor for disease progression for ovarian cancer patients (P = 0.016).
conclusionDHFR level measurement was a valuable prognostic biomarker for chemo-sensitivity of ovarian cancer. Molecular analysis for DHFR variants will provide important evidence for chemotherapy regimen options.
Indexed as
Identifiers
31933990PMC6947109W3027181512What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.